<?xml version="1.0" encoding="UTF-8"?>
<p id="p0145">Although several studies have been available suggesting remdesivir give no proper results against COVID-19. Wang et al carried out randomised, double-blind, placebo-controlled, multicentre trial of remdesivir on 237 COVID-19 patients. The 158 patients were given Remdesivir out of 237 patients, and 79 patients were given placebo formulation. It was found that clinical improvement in the remdesivir group was not significantly different to that of the control group. Remdesivir had a numerically faster time to clinical improvement in comparison to placebo. Mortality rate of both the groups was similar [
 <xref rid="bb0200" ref-type="bibr">40</xref>].
</p>
